Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report
Authors:
Open Access
- 23 September 2026
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 32 (5) , 1-7
Abstract
Immune checkpoint inhibitors (ICIs) are widely incorporated into first‑line treatment regimens for advanced hepatocellular carcinoma (HCC). Nevertheless, the growing incidence of immune‑related adverse events (irAEs), particularly dermatologic toxicities, poses a substantial challenge to the continuation of anticancer therapy. The present study describes a case of tislelizumab‑associated psoriasis in a patient with hepatitis C virus (HCV)‑related HCC, emphasizing the need for prompt recognition and individualized management. A 60‑year‑old man with stage IIIA HCC and chronic HCV infection developed progressively worsening erythematous plaques with scaling during the eighth cycle of tislelizumab plus bevacizumab. Histopathological examination of a skin biopsy supported a diagnosis of pustular psoriasis. A Naranjo Adverse Drug Reaction Probability Scale score of 7 suggested that tislelizumab was the probable causative agent. Because the patient had type 2 diabetes mellitus and declined systemic glucocorticoid treatment, tislelizumab was discontinued, and narrow‑band ultraviolet B (NB‑UVB) phototherapy was administered in combination with topical corticosteroids. The skin lesions markedly resolved with no recurrence during the 6‑week follow‑up period. To the best of our knowledge, this is the first report of NB‑UVB phototherapy successfully treating ICI‑induced psoriasis. This case underscores the need for close monitoring of cutaneous irAEs during ICI therapy and suggests that NB‑UVB phototherapy may be an effective alternative to systemic corticosteroids for managing ICI‑induced psoriasis, particularly in patients where preservation of antitumor immunity is desirable or systemic steroids are contraindicated. Regular multidisciplinary follow‑up and individualized management of adverse events are essential for optimizing both oncological and dermatological outcomes.Keywords
This publication has 33 references indexed in Scilit:
- Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular CarcinomaJAMA Oncology, 2023
- Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic reviewJournal of the American Academy of Dermatology, 2023
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Insulin allergy: a diagnostic and therapeutic strategy based on a retrospective cohort and a case–control studyDiabetologia, 2022
- Advances on immune-related adverse events associated with immune checkpoint inhibitorsFrontiers of Medicine, 2020
- Immune checkpoint inhibitor–related dermatologic adverse eventsJournal of the American Academy of Dermatology, 2020
- Tislelizumab: First ApprovalDrugs, 2020
- Cutaneous Manifestations of Diabetes Mellitus: A ReviewAmerican Journal of Clinical Dermatology, 2017
- A review of phototherapy protocols for psoriasis treatmentJournal of the American Academy of Dermatology, 2011
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapyCancer Immunology, Immunotherapy, 2005